BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the unblinding of the Phase 3 TITAN study evaluating ERLEADA® (apalutamide) plus androgen deprivation therapy (ADT) in the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

The WIRB-Copernicus Group®'s (WCG™) Market Intelligence & Insights Division has acquired First Clinical Research LLC, organizer of the MAGI (Model Agreements & Guidelines International) Clinical Research Conference, which unifies the clinical research ecosystem by facilitating communication and the sharing of best practices among members.

Charles River Laboratories International, Inc (NYSE: CRL) and Toxys have entered into an agreement to offer access to ToxTracker® in North America.

Magnolia Medical Technologies today announced a $20 million Series C financing round to scale the company’s infrastructure and market initiatives to meet the rapidly growing demand for its Steripath® Gen2 Initial Specimen Diversion Device® (ISDD®).

Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Company”), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, today will celebrate the official opening of its most recent Global Logistics Center, based in Amsterdam, The Netherlands.

Beckman Coulter Life Sciences today announced its acquisition of Labcyte, a privately held, acoustic liquid handling company based in San Jose, California.

Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) submitted responses to the European Medicines Agency (EMA) Day 120 questions on 23 January 2019. The due date for response to the questions was 25 January.

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today provided updates on several ongoing and planned clinical trials with OP0201, the company’s lead product candidate being developed for otitis media.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Bill Peck, Ph.D., chief technology officer, participated in the Future Health Threats Initiative 2019, a conference designed to encourage public-private cooperation to strengthen health security in Africa.

“We are urging a plumber, electrician, mechanic, machinist, welder, insulator or any other type of skilled trades worker with mesothelioma or asbestos exposure lung cancer in Ohio or their family to call us anytime at 800-714-0303 so we can explain how incredibly vital it is to have a team of the nation’s most skilled mesothelioma lawyers working on their compensation claim.